Answers are grounded in this paper and cite their sources.
Circulating Treg cells represent a promising potential dynamic biomarker to predict efficacy and differentiate atypical responses, including pseudoprogression and hyperprogression, after immunotherapy in patients with NSCLC.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: